ReVision Optics (RVO) secured a $10 million credit facility from Square 1 Bank, a division of Pacific Western Bank.
RVO recently received approval from the U.S. Food and Drug Administration (FDA) for its Raindrop Near Vision Inlay for the surgical correction of presbyopia. Proceeds from the credit facility will be used for working capital purposes, including commercial operations.
Rilus Graham, senior vice president in Square 1’s life sciences practice, said, “RVO’s innovative solution for presbyopia has produced excellent post-treatment outcomes and high rates of patient satisfaction. Square 1 is excited to support RVO’s future strategic growth opportunities and commercialization efforts.”
San Diego, CA-based Revision Optics focuses on the development and commercialization of innovative optical solutions dedicated to presbyopic vision correction.